** Shares of drug developer ARS Pharmaceuticals SPRY.O rise 2.6% to $11.15 premarket
** Co said late on Wednesday the U.S. FDA approved the expanded use of nasal spray for severe allergic reactions in patients who weigh between 15 kg and 30 kg
** The spray, sold under the brand name neffy, will be dosed at 1 mg for the new patient population
** Neffy is designed to be given at the first sign of a severe allergic reaction, and has been previously approved for people above 30 kg at dose of 2 mg
** SPRY has risen 21.5% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。